Septerna, Inc. has seen its shares rise over 315% since May 2025, fueled by its focus on GPCR drug discovery and a strategic collaboration with Novo Nordisk targeting multiple receptors. The partnership generated $26.7 million in Q2 collaboration revenue and launched a new R&D program. Key upcoming catalysts include a pivotal data readout for SEP-479, an oral treatment for hypoparathyroidism, expected in Q1 2027, and a strategic shift in SEP-631 development toward broader mast cell diseases amid competitive pressures. These developments position Septerna as a notable biotech investment opportunity with significant growth potential.
Uber Technologies maintains a Buy rating amid stock volatility, driven by strong core business and strategic investments. The company is tackling autonomous vehicle risks by investing $10 billion and planning to integrate 120,000 AVs. Uber's global e...
Stifel Nicolaus increased its price target for Donaldson Company to $95, reflecting a 3.77% potential upside. Donaldson reported record fiscal 2026 results with $3.9 billion in sales, a 5% increase, and adjusted EPS up 8% to $3.98. The company also a...
Cema-cel treatment achieved minimal residual disease (MRD) clearance in 58.3% of patients compared to 16.7% under observation, with a 97.7% median reduction in circulating tumor DNA by day 45, indicating strong early biological activity. The FDA gran...
Investors holding the Vanguard Total International Stock ETF (VXUS) inside IRAs lose the foreign tax credit on dividends because retirement accounts cannot claim this credit. Foreign governments withhold taxes on dividends before they reach the fund,...
Power Metallic Mines Inc. has initiated a $200,000 digital marketing campaign with Native Ads to promote its upcoming Mineral Resource Estimate (MRE) and Preliminary Economic Assessment (PEA). The campaign focuses on investor engagement through digit...
